Stocks · News reference
HSBC analyst Rajesh Kumar maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $290 to $320.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Three sectors are higher and eight are lower in Thursday’s regular session, with growth, cyclical and defensive sectors each represented among the top three. The leaders are separated rather than
The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI®
DGRO, a smart beta ETF sponsored by BlackRock, provides broad exposure to large-cap dividend growth stocks with a low 0.08% expense ratio and $43.03 billion in assets. The fund has delivered 12.35% year-to-date returns and 16.02% one-year returns with medium risk profile, holding 398 stocks across sectors led by Financials (20.9%). Top holdings include Microsoft, Johnson & Johnson, and JPMorgan Chase.